Why the study?
Growing evidence indicates that BDNF/TrkB signaling is expressed in the cardiovascular system and linked to cardiovascular disease, but challenges remain in translating these findings into novel therapeutic strategies.
Key points are not available for this paper at this time.
Design
Review
BDNF may aid cardiovascular risk stratification; leaves open its clinical adoption pending prospective validation.
Brain-derived neurotrophic factor (BDNF) is one of the most abundantneurotrophins in the central nervous system. Numerous studies suggestthat BDNF has extensive roles by binding to its specific receptor, tropomyosin-related kinase receptor B (TrkB), and thereby triggering downstream signaling pathways. Recently, growing evidence highlightsthat the BDNF/TrkB pathway is expressed in the cardiovascular system andclosely associated with the development and outcome of cardiovascular diseases (CVD), including coronary artery disease, heart failure, cardiomyopathy, hypertension, and metabolic diseases. Furthermore, circulating BDNF has also been revealed as a new potential biomarker for both diagnosis and prognosis of CVD. In this review, we discuss the current evidence of the emerging role of BDNF/TrkBsignalingand address the challenges that remain in translating these discoveries to novel therapeutic strategies for CVD.
No takes yet. Share an insight, caveat, or question.
Hang et al. (2021) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: